Episode

Global Collaboration: East - West Exchange to Learn from Each Other

Podcast
Diabetes Insights - Breakthroughs and Innovators
Published
Jul 3, 2026
Duration seconds
499
Processing state
not_requested
Canonical source
https://diabetes-insights.podigee.io/70-global-collaboration-east-west-exchange-to-learn-from-each-other
Audio
https://audio.podigee-cdn.net/2533720-m-ba61c13e15a3ba4a526eb0e596fdb4fa.mp3?source=feed
JSON
/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/global-collaboration-east-west-exchange-to-learn-from-each-other
Markdown
/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/global-collaboration-east-west-exchange-to-learn-from-each-other.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/diabetes-insights-breakthroughs-and-innovators-7109701/episodes/global-collaboration-east-west-exchange-to-learn-from-each-other/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/diabetes-insights-breakthroughs-and-innovators-7109701/global-collaboration-east-west-exchange-to-learn-from-each-other.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, EASD tv host Vivienne Parry speaks with Prof. Daisuke Yabe (Kyoto University) about the growing global impact of EASD and the importance of international collaboration in diabetes research. Prof. Yabe explains the key differences between diabetes phenotypes in Europe and East Asia, highlighting how obesity, insulin resistance and beta cell dysfunction vary across populations. He discusses how sharing these perspectives is driving better research, stronger international partnerships and improved diabetes care worldwide. The conversation also explores one of the most exciting developments in regenerative medicine: iPS cell-derived islet transplantation. Professor Yabe shares how clinical trials in Japan are addressing donor shortages using induced pluripotent stem cells and discusses the progress being made towards more scalable cell therapies for people living with type 1 diabetes.